PAN submits letter in support of the NIH Clinical Integrity Act

The PAN Foundation submitted a letter to Senate and House representative sponsors in support of their reintroduction of the NIH Clinical Integrity Act. A bipartisan and bicameral bill, the NIH Clinical Integrity Act seeks to bolster participation in NIH funded clinical trials to ensure that treatments and interventions are safe and effective for all patient populations. Reflecting America’s diversity in clinical trial participation is important as people may experience the same disease differently. Clinical trials should include people with a variety of lived experiences and living conditions, as well as characteristics like race and ethnicity, age, sex, and sexual orientation, so that all communities can benefit from scientific advances. The NIH Clinical Integrity Act importantly seeks to increase such populations in NIH clinical trials.

• Read our letter to the Senate
• Read our letter to the House
• Explore policy letters and testimony
• Learn about inclusivity and clinical trials